By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 150.97 |
Change Today | $ -1.24 |
% Change | -0.81 % |
52 Week High | $191.56 |
52 Week Low | $118.84 |
Volume | 83 |
Shares Issued | 145.80m |
Market Cap | $22,011m |
RiskGrade | 259 |
You are here: research